Short duration of aspirin and prasugrel
Drugaspirin 75 mg/day for 1 months plus prasugrel 10 mg/day (5 mg/day) for 1 year, followed by lifelong aspirin 75 mg/day after 1 year
NCT Number: NCT06718179
The SORT OUT XII dual antiplatelet treatment (DAPT) duration trial, is a clinical randomized controlled superiority and non-inferiority trial to compare whether prasugrel alone versus prasugrel plus aspirin from month 1 to month 12 after percutaneous coronary intervention with and everolimus-eluting stent in patients with acute coronary syndromes (1) is superior regarding clinically relevant bleeding and (2) non-inferior regarding safety (cardiac death, myocardial infarction, definite stent thrombosis, ischemic stroke or clinically driven target lesion revascularization)
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 4
Aalborg University Hospital, Aalborg, Denmark
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
aspirin 75 mg/day for 1 months plus prasugrel 10 mg/day (5 mg/day) for 1 year, followed by lifelong aspirin 75 mg/day after 1 year
aspirin 75 mg/day lifelong plus prasugrel 10 mg/day (5 mg/day) for 1 year
Time frame: 1 year
Clinically relevant bleeding is defined a "Bleeding Academic Research Consortium" (BARC) where BARC group 2, 3 and 5 are registered
Time frame: 1 year
Major adverse cardiovascular or cerebrovascular events (MACCE) is defined as a composite of cardiac death, myocardial infarction, definite stent thrombosis, ischemic stroke or clinically driven target lesion revascularization)
Time frame: 1 year
Clinically relevant bleeding is defined a "Bleeding Academic Research Consortium" (BARC) 2, 3 and 5, where BARC group 2, 3 and 5 are registered
Time frame: 1 year
All-cause death is defined as any death
Time frame: 1 year
Cardiac death is defined as death resulting from cardiovascular causes: death caused by acute myocardial infarction, death caused by sudden cardiac, including unwitnessed, death, death resulting from heart failure, death caused by cardiovascular procedures. Undetermined cause of death is defined as a death not attributable to any other category because of the absence of any relevant source documents. Such deaths will be classified as cardiovascular for end point determination
Time frame: 1 year
Myocardial infarction diagnosis follows "The Joint ESC/ACCF/AHA/WHF Task Force on "Third Universal Definition of acute myocardial infarction",which has been adapted by Academy Research Consortium. Acute myocardial infarction not related to other than index lesion is defined as any acute myocardial infarction that is not clearly attributable to a non-target vessel
Time frame: 1 year
Definite stent thrombosis is defined as:
Angiographic confirmation of stent thrombosis. The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent or in a side branch originating from the stented segment and the presence of at least one of the following criteria:
Acute onset of ischemic symptoms at rest New electrocardiographic changes suggestive of acute ischemia Typical rise and fall in cardiac biomarkers (refer to definition of spontaneous myocardial infarction) Or Pathological confirmation of stent thrombosis
Time frame: 1 year
Target lesion revascularization is defined as a repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment including the 5-mm margin proximal and distal to the stent
Time frame: 1 year
Ischemic stroke is defined from the Neurologic Academic Research Consortium (Neuro-ARC):
Classification on the basis of symptoms and evidence of CNS injury, including overt (acutely symptomatic) CNS injury (Type 1), covert (acutely asymptomatic) CNS injury (Type 2), and neurological dysfunction (acutely symptomatic) without CNS injury (Type 3)
Time frame: 1 month and 1 year
Health-related quality of life (HRQoL) will be assessed by the health state classifier EQ-5D
Time frame: 1 month and 1 year
Angina status is based on the Canadian Cardiovascular Society classification system (SaQ)
Contact information is provided by the study sponsor or research team.
Evald H Christiansen, MD
CONTACT
Lisette O Jensen, MD
CONTACT
Odense University Hospital
Other
Randomized Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Intervention and Everolimus-eluting Stents (SORT OUT XII DAPT Duration Trial)
Acronym: SORT OUT DAPT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07258290
Acute Coronary Syndrome, Angina Pectoris
Washington D.C., District of Columbia, United States
View Trial DetailsNCT07032389
Acute Coronary Syndrome, Cardiovascular Diseases
Dallas, Texas, United States
View Trial DetailsNCT06332859
Acute Coronary Syndrome, Cardiomyopathies
Bad Tatzmannsdorf, Burgenland, Austria
View Trial DetailsNCT01311323
Acute Coronary Syndrome, Cardiovascular Diseases
Chrzanów, Malopolska, Poland
View Trial Details